B
Bull
Bull · 25%SXTP
$4.69
Precio del escenario
$1.030
-0.029 (-2.83%)Al cierre
Loading chart…
- High
- 1.120
- Open
- 1.090
- VWAP
- 1.05
- Vol
- 23.94K
- Mkt Cap
- 3.28M
- Low
- 1.010
- Amount
- 25.22K
- EV/EBITDA, TTM
- 0.00
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Métricas de valoración
The current forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP) is -0.14, compared to its 5-year average forward P/E of -0.88.
Alphio AI Price Scenarios for SXTP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.508-17NASDAQ.COM60 Degrees Pharmaceuticals Q2 Financial Results Analysis
8.507-31NASDAQ.COM60 Degrees Pharmaceuticals Announces Private Placement Financing
8.507-30Globenewswire60 Degrees Pharmaceuticals Completes Private Placement Agreement
8.507-30Newsfilter60 Degrees Pharmaceuticals Completes Private Placement Agreement
7.507-09NASDAQ.COM60 Degrees Pharmaceuticals Signs Exclusive Agreement with Florida State University
SXTP FAQ — answered by Alphio AI
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.